MG Biotherapeutics, LLC - a Medtronic-Genzyme joint venture - is developing novel therapies that combine biologics and delivery devices for the treatment of advanced cardiovascular disease. The company is currently focusing on cellular therapies that can be delivered directly to the heart, to investigate the potential for repairing tissue damaged as a result of a heart attack